Navigation Links
Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
Date:9/3/2009

SAN DIEGO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 10:30 a.m. Eastern Time at the Four Seasons Hotel in New York City.
  • Thomas Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at 3:50 p.m. Eastern Time at the Four Seasons Hotel in Boston.
  • ThinkEquity's 6th Annual Growth Conference on Tuesday, September 15, 2009 at 10:30 a.m. Pacific Time at the St. Regis Hotel in San Francisco.
  • UBS Global Life Sciences Conference 2009 on Tuesday, September 22, 2009 at 1:00 p.m. Eastern Time at the Grand Hyatt New York in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
2. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
4. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
5. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
6. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
10. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
11. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John ... Mr. Kelley, a recognized leader and mentor in the Denver area business ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and data management ... The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” , “From ... end users facing some of the most complex data challenges in the industry,” said ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Martine ... United Therapeutics will provide an overview and update on ... Annual Health Care Conference. The presentation ... 10:00 a.m. Eastern Time, and can be accessed via ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/9/2016)... 9, 2016  Crossmatch ® , a leading ... today announced the addition of smart features to ... multi-factor authentication platform. New contextual and application-specific authentication ... security where it,s needed most — while minimizing ... . --> Washington, DC ...
Breaking Biology News(10 mins):